Testing effectiveness (Phase 2)Ended earlyNCT00570258
What this trial is testing
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Who this might be right for
Metastatic Breast Cancer
University of Arkansas 27